On April 25, ALL 8 CMS Medicare Administrative Contractors (MACs) released proposed LCD/LCAs for Skin Substitutes/CTPs for DFUs and VLUs.

I am not trying to push the use of this drug. I am just looking for answers to the hopeless feeling of seeing another patient with a BMI over 35 who needs wound care.

Yesterday morning, 8 MACs issued nearly identical draft coverage policies for the use of CTPs (“skin subs”) in diabetic foot ulcers and venous leg ulcers.

I don’t know whether giving the condition a name is helpful to those who are affected by it, but maybe doing so will make it easier for us to talk about it with patients and friends.

Although the HBOT PA process was limited to 3 states, HBOT utilization decreased nationwide and today remains at a 16 year low.

These data support previous studies that demonstrate the clinical benefits and cost-effectiveness of HBO2 in conjunction with routine interventions.

I am trying to find ways to visually depict our current situation with regard to Cellular and/or Tissue-based products (CTPs).

The policy also includes an extensive list of products that will NOT be covered by United Healthcare.

Here’s a visual example of the insanity of Cellular Tissue Product (CTP) pricing and the problem with ASPs.